# A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

> **NCT06227910** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 396 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab
- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06227910
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2027-06-08
- **Final completion:** 2028-08-01
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227910, "A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06227910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*